PMC:7242013 / 9855-10032 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T32","span":{"begin":84,"end":89},"obj":"Body_part"}],"attributes":[{"id":"A32","pred":"fma_id","subj":"T32","obj":"http://purl.org/sig/ont/fma/fma7197"}],"text":"8 All associations recommend limiting LT to patients with high Model for End‐Stage Liver Disease scores, risk for decompensation, or hepatocellular carcinoma (HCC) progression."}

{"project":"LitCovid-PubTator","denotations":[{"id":"287","span":{"begin":160,"end":163},"obj":"Gene"},{"id":"289","span":{"begin":45,"end":53},"obj":"Species"},{"id":"290","span":{"begin":74,"end":97},"obj":"Disease"},{"id":"291","span":{"begin":134,"end":158},"obj":"Disease"}],"attributes":[{"id":"A287","pred":"tao:has_database_id","subj":"287","obj":"Gene:619501"},{"id":"A289","pred":"tao:has_database_id","subj":"289","obj":"Tax:9606"},{"id":"A290","pred":"tao:has_database_id","subj":"290","obj":"MESH:D058625"},{"id":"A291","pred":"tao:has_database_id","subj":"291","obj":"MESH:D006528"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"8 All associations recommend limiting LT to patients with high Model for End‐Stage Liver Disease scores, risk for decompensation, or hepatocellular carcinoma (HCC) progression."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T30","span":{"begin":84,"end":89},"obj":"Body_part"}],"attributes":[{"id":"A30","pred":"uberon_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"8 All associations recommend limiting LT to patients with high Model for End‐Stage Liver Disease scores, risk for decompensation, or hepatocellular carcinoma (HCC) progression."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T119","span":{"begin":84,"end":97},"obj":"Disease"},{"id":"T120","span":{"begin":134,"end":158},"obj":"Disease"},{"id":"T121","span":{"begin":149,"end":158},"obj":"Disease"},{"id":"T122","span":{"begin":160,"end":163},"obj":"Disease"}],"attributes":[{"id":"A119","pred":"mondo_id","subj":"T119","obj":"http://purl.obolibrary.org/obo/MONDO_0005154"},{"id":"A120","pred":"mondo_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/MONDO_0007256"},{"id":"A121","pred":"mondo_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/MONDO_0004993"},{"id":"A122","pred":"mondo_id","subj":"T122","obj":"http://purl.obolibrary.org/obo/MONDO_0007256"}],"text":"8 All associations recommend limiting LT to patients with high Model for End‐Stage Liver Disease scores, risk for decompensation, or hepatocellular carcinoma (HCC) progression."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T79","span":{"begin":39,"end":41},"obj":"http://purl.obolibrary.org/obo/CLO_0007408"},{"id":"T80","span":{"begin":84,"end":89},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T81","span":{"begin":84,"end":89},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"}],"text":"8 All associations recommend limiting LT to patients with high Model for End‐Stage Liver Disease scores, risk for decompensation, or hepatocellular carcinoma (HCC) progression."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T31","span":{"begin":39,"end":41},"obj":"Chemical"}],"attributes":[{"id":"A31","pred":"chebi_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_73589"}],"text":"8 All associations recommend limiting LT to patients with high Model for End‐Stage Liver Disease scores, risk for decompensation, or hepatocellular carcinoma (HCC) progression."}

{"project":"LitCovid-sentences","denotations":[{"id":"T117","span":{"begin":0,"end":177},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"8 All associations recommend limiting LT to patients with high Model for End‐Stage Liver Disease scores, risk for decompensation, or hepatocellular carcinoma (HCC) progression."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T24","span":{"begin":84,"end":97},"obj":"Phenotype"},{"id":"T25","span":{"begin":134,"end":158},"obj":"Phenotype"}],"attributes":[{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0001392"},{"id":"A25","pred":"hp_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/HP_0001402"}],"text":"8 All associations recommend limiting LT to patients with high Model for End‐Stage Liver Disease scores, risk for decompensation, or hepatocellular carcinoma (HCC) progression."}